ResMed/$RMD
1D1W1MYTD1Y5YMAX
Capital at risk
About ResMed
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
- Ticker
- $RMD
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 11,370
- Headquarters
- San Diego, United States
- Website
- www.resmed.com
ResMed Metrics
BasicAdvanced
$32B
21.20
$10.43
0.77
$2.46
1.19%
Price and volume
Market cap
$32B
Beta
0.77
52-week high
$284.87
52-week low
$180.27
Average daily volume
1.3M
Dividend rate
$2.46
Financial strength
Current ratio
3.1
Quick ratio
1.796
Long term debt to equity
0.082
Total debt to equity
0.125
Dividend payout ratio (TTM)
22.95%
Profitability
EBITDA (TTM)
2,095.775
Gross margin (TTM)
61.62%
Net profit margin (TTM)
26.94%
Operating margin (TTM)
33.96%
Effective tax rate (TTM)
20.64%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
14.00%
Return on equity (TTM)
24.27%
Valuation
Price to earnings (TTM)
21.203
Price to revenue (TTM)
5.693
Price to book
4.84
Price to tangible book (TTM)
9.93
Price to free cash flow (TTM)
19.76
Free cash flow yield (TTM)
5.06%
Free cash flow per share (TTM)
11.192
Dividend yield (TTM)
1.11%
Forward dividend yield
1.19%
Growth
Revenue change (TTM)
9.85%
Earnings per share change (TTM)
9.67%
3-year revenue growth (CAGR)
10.21%
10-year revenue growth (CAGR)
11.89%
3-year earnings per share growth (CAGR)
19.64%
10-year earnings per share growth (CAGR)
15.40%
3-year dividend per share growth (CAGR)
10.89%
10-year dividend per share growth (CAGR)
6.91%
What the Analysts think about ResMed
Analyst ratings (Buy, Hold, Sell) for ResMed stock.
Analyst projections of the future price of ResMed stock.
Bulls say / Bears say
Fiscal 2026 revenue rose 10%, while non-GAAP earnings per share climbed 17% and free cash flow reached $1.6 billion. This points to strong demand and the ability to turn sales growth into cash and earnings. (Last10K)
ResMed says around 80% of people with sleep apnoea in the US remain undiagnosed, giving it room to expand its patient funnel. Its ŌURA partnership aims to turn wearable-driven awareness into clinical assessment and care. (ResMed)
ResMed is still rolling out its AirSense 11 platform internationally and has launched newer AirCurve 11 devices for patients with more complex breathing needs. Those launches give it products to support growth in markets where its latest platforms are not yet fully established. (The Motley Fool)
A field safety notice led ResMed to suspend new Astral ventilator sales for fiscal 2027, with management estimating about a $75 million revenue headwind. The related charge also weighed on fourth-quarter GAAP gross margin, and the suspension makes the near-term outlook less dependable. (The Motley Fool)
Philips is expected to return to the US sleep-device market in 2027 after years away, creating a risk of tougher competition for ResMed. A stronger rival could put pressure on prices or market share. (Market Index)
Higher freight, fuel, logistics and component costs are pressuring margins, and management said productivity alone can no longer offset inflation. ResMed is introducing modest price rises, but customers with tight reimbursement economics may resist them. (StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2026.
ResMed Financial Performance
Revenues and expenses
ResMed Earnings Performance
Company profitability
Upcoming events
No upcoming events
ResMed News
AllArticlesVideos
Funds containing ResMed
AllEURGBPUSD
Fund name | Fund size | $RMD weighting |
|---|---|---|
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.52% |
iShares MSCI World Health Care Sector Advanced€CBUF | €606M | 0.43% |
iShares S&P 500 Equal Weight€O4J0 | €4.3B | 0.21% |
iShares S&P 500 Equal Weight£EWSP | £3.7B | 0.21% |
iShares MSCI USA Islamic$ISDU | $594M | 0.18% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.